ACM
PSTX

Aisling Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Aisling Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,043,267
Closed -$10M – 15
2024
Q4 		$10M Hold
1,043,267
– – 3.55% 5
2024
Q3 		$2.98M Hold
1,043,267
– – 1.14% 9
2024
Q2 		$3.05M Hold
1,043,267
– – 1.32% 9
2024
Q1 		$3.33M Hold
1,043,267
– – 1.13% 9
2023
Q4 		$3.51M Hold
1,043,267
– – 1.05% 9
2023
Q3 		$2.48M Hold
1,043,267
– – 1.02% 11
2023
Q2 		$1.84M Hold
1,043,267
– – 0.9% 11
2023
Q1 		$3.21M Hold
1,043,267
– – 1.55% 10
2022
Q4 		$5.53M Hold
1,043,267
– – 3.65% 7
2022
Q3 		$3.68M Hold
1,043,267
– – 2.45% 8
2022
Q2 		$2.69M Hold
1,043,267
– – 1.92% 10
2022
Q1 		$4.67M Hold
1,043,267
– – 2.52% 10
2021
Q4 		$7.11M Hold
1,043,267
– – 2.51% 12
2021
Q3 		$7.61M Hold
1,043,267
– – 1.52% 11
2021
Q2 		$10.5M Hold
1,043,267
– – 1.67% 11
2021
Q1 		$9.96M Hold
1,043,267
– – 1.79% 10
2020
Q4 		$11.4M Hold
1,043,267
– – 1.97% 8
2020
Q3 		$9.25M Buy
+1,043,267
New +$11.9M 2.96% 7

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Aisling Capital Management's PSTX Position: Q1 2025 in Review

Aisling Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 1,043,267 shares — an estimated $10M sold.

Aisling Capital Management first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $11.4M in Q4 2020. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Aisling Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Aisling Capital Management sold 1,043,267 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $10M.
  • Aisling Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
  • Aisling Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $11.4M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Aisling Capital Management's 13F filing for Q1 2025, filed 13 May 2025.